Saturday, October 3, 2026

USD/EUR Went Down By Over 1% In The Last 21 Sessions

USD/EUR Went Down By Over 1% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 1.56% for the last 21 sessions. At 04:10 EST on Monday, 24 July, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 1.759% up from its 52-week low and 13.9% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.18%, a negative 0.08%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.24% (last week), 0.33% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd: weekly forecast 23rd July - 29th July - 23 July 2023. According to DailyForex on Sunday, 23 July, "The EUR/USD near 1.11000 should be watched early this week to see if the support level can be sustained.", "However, after reaching this apex long-term high early last week, the EUR/USD also mirrored broad Forex conditions and started to produce a rather fast sell-off which escalated as the weekend approached. "
  • Eur/usd steadies above 1.1100 after three-day losing streak, eu/us PMI data, ecb, fed eyed. According to FXStreet on Sunday, 23 July, "Amid these plays, Wall Street closed mixed while the US Treasury bond yields posted a mild weekly gain, which in turn favors US Dollar's further upside and weighs on the EUR/USD price.", "Hence, the latest recovery in the US Dollar appears to lack support from the top-tier US inflation and employment data, which in turn prods the EUR/USD sellers as the key week begins."
  • Eur/usd holds steady above 1.1100 mark, eyes flash euro zone/us pmis for some impetus. According to FXStreet on Monday, 24 July, "This will be followed by the European Central Bank (ECB) meeting on Thursday, which should allow investors to determine the near-term trajectory for the EUR/USD pair. ", "This, in turn, might hold back traders from placing aggressive directional bets and should help limit any meaingful downside for the EUR/USD pair, at least for the time being. "
  • Eur/usd price analysis: edges higher past 1.1100-1090 support zone ahead of eurozone, US PMI. According to FXStreet on Monday, 24 July, "In a case where the EUR/USD remains bearish past 1.1000, an ascending support line from May 31, close to 1.0920, will be the key support before pleasing the pair sellers.", "On the flip side, a clear break of the 1.1090 support could quickly drag the EUR/USD price toward another horizontal support area comprising levels marked since late June, around 1.1010-1000 at the latest."
  • Eur/usd: signs of US disinflation to lift the pair toward 1.15 – ING. According to FXStreet on Monday, 24 July, "Strong signs of US disinflation and bullish steepening of the US yield curve should be a EUR/USD positive. "

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com